But the company hasn’t given details, and used a historical control rather than the study’s own control arm.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.

Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.

A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.

A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?

The company defends its cancer strategy, and says it's not a me-too developer.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.